Penn Medicine Launched Proton Therapy Clinical Trial

The study tests a precision 3D-targeted FLASH radiation technique for patients with recurrent head and neck cancer.

Updated on Oct. 1, 2026 in Cancer

Penn Medicine Launched Proton Therapy Clinical Trial

Live Poll

Would you prefer a faster, high-intensity radiation treatment even if it is still experimental?

Penn Medicine has initiated a Phase I clinical trial at the Roberts Proton Therapy Center in Philadelphia. The study utilizes a new conformal FLASH proton therapy designed to treat head and neck cancers with high precision.

Why it matters

The trial seeks to provide a faster, more tolerable alternative for patients facing limited options and the severe side effect profiles typically associated with conventional radiation therapy.

The clinical trial utilizes a protocol of five treatments over 10 days. This regimen is being tested against standard conventional radiation treatments which typically require between 25 and 35 fractions.

The players

Penn Medicine

This is a health system based in Philadelphia that operates numerous research facilities and hospitals.

Ion Beam Applications

This is the company sponsoring the study after receiving FDA approval through an Investigational Device Exemption.

Roberts Proton Therapy Center

This facility in Philadelphia serves as the clinical site for the new proton therapy trial.

The details

FLASH therapy delivers radiation in bursts lasting less than one second, while 3D mapping imaging allows for targeted beam delivery to specific tumor boundaries. This approach aims to reduce both treatment-related side effects and the total time patients spend in clinical facilities.

The clinical trial officially launched in October 2026.
A new proton therapy center is expected to open in late 2027.

Deeper Dive

This clinical trial follows the precedent set by the Penn Medicine pet dog FLASH proton therapy trial. The success of those veterinary studies informed the move into human trials to evaluate the potential for expanding FLASH techniques to broader cancer types.

The study offers a significantly compressed treatment schedule of five sessions, potentially reducing the burden on patients compared to standard radiation protocols. Eligible patients who are not candidates for surgery may find this trial provides a new pathway for managing recurrent disease.

The takeaway

This trial represents a shift toward ultra-fast radiation delivery that aims to minimize damage to healthy tissue. Patients should consult with their oncologists to determine if they meet the specific enrollment criteria for such emerging clinical technologies.